Monsoon Communications is a premium investor and public relations firm, adding shareholder value to small and mid-cap companies.
Melbourne, Australia
Joined June 2012
- Tweets675
- Following754
- Followers408
- Likes119
Next Tue: #TwilightInvestorBriefing, Water → Agri → Food
Supported by @RSM_au, world-leading provider of audit, tax & consulting services — we'll present:
💧 Rivco (ASX:RIV)
🌾 Warakirri Agri Fund
🥛 OMG (ASX:OMG)
Spots are limited, register now. ⬇️
docs.google.com/forms/d/e/1F…
Highlights:
💧 Rivco (ASX:RIV): only ASX-listed water asset co, ~22% discount to post-tax NAV, 80% leased
🌾 Warakirri Agri Fund: 9.4yr WALE, 6.9% gross rental yield, quarterly distributions since 2021
🥛 OMG (ASX:OMG): maiden +EBITDA, sales +59% YoY
#TwilightInvestorBriefing
#TwilightInvestorBriefing returns with water, agri and food investment opportunities.
📅 Tue 27 Oct | 4PM AEDT | Melbourne
Register now ⬇️
docs.google.com/forms/d/e/1F…
Thanks to the world-leading provider of audit, tax & consulting services, @RSM_au, for the generous support!
Highlights:
💧 Rivco (ASX:RIV): only ASX-listed water asset co, ~22% discount to post-tax NAV, 80% leased
🌾 Warakirri Agri Fund: 9.4yr WALE, 6.9% gross rental yield, quarterly distributions since 2021
🥛 OMG (ASX:OMG): maiden +EBITDA, sales +59% YoY
#TwilightInvestorBriefing
#TwilightInvestorBriefing: Neural Biotechs Sydney featured three #ASX companies advancing neurology and stroke care where patients have few or no options: Neuren ($NEU), EMVision ($EMV), @ArgenicaT ($AGN).
Miss the evening? Watch the recording. ⬇️
youtu.be/I70Yxh-sd1Y
#TwilightInvestorBriefing Highlights:
$NEU: record US$125m Q2 sales, EU approval, US$35m milestone in sight
$EMV: pivotal FDA trial at Mayo Clinic & UCLA, world-first portable brain scanner
$AGN: xaranetide clears all FDA safety assays, efficacy in severest stroke patients
Our gratitude to @FB_Rice, one of Australia's leading Intellectual Property firms, for the generous sponsorship and hosting that makes #TwilightInvestorBriefing possible!
It's a wrap on #BiotechShowcase 2026! Thank you to @PeakAsset1 and @FB_Rice for a great partnership, and biotech community who joined us on 3 September.
Catch the recording ⬇️
youtu.be/KtiawGmr7xI
Session 2: Investor Panel
Moderator: Michael Woods (Newburyport Partners)
Panelists:
⭐️ Matt McNamara (Horizon 3 Healthcare)
⭐️ Bob Soh (Brandon Capital)
⭐️ Dr Amir Zalcenstein (SYNthesis BioVentures)
#BiotechShowcase
Session 3 | Moderator: Madeleine Williams (Canaccord)
Presenters: @BiotronLimited, @AvechoLtd, @ampliatx, Neuren Pharmaceuticals
#BiotechShowcase #ASX
🔔 Update: #TwilightInvestorBriefing Sydney starting time is changed to 4.30 PM AEST.
Facilitated by @FB_Rice, meet three #ASX companies at the forefront of stroke care and rare neurological disease treatment.
Last call to register ⬇️
docs.google.com/forms/d/1xnH…
✅ $NEU
Record US$125m Q2 sales, EU approval unlocks US$35m milestone
✅ $AGN
Xaranetide clears all FDA safety assays, Phase 2b incoming
✅ $EMV
World-first portable brain scanner, pivotal FDA trial underway at Mayo Clinic, Mount Sinai & UCLA
#TwilightInvestorBriefing #ASX
#TwilightInvestorBriefing is coming to Sydney — join us & @FB_Rice for an evening with three ASX companies at the forefront of stroke care and rare neurological disease treatment.
Register now ⬇️
docs.google.com/forms/d/e/1F…
Recording of #TwilightInvestorBriefing featuring promising #ASX-listed cancer therapy biotechs: @RacuraOncology, @ampliatx & @PTX_AUS is now available.
Thank you to @FB_Rice and Lee Miles (Partner, FB Rice Sydney) for generously supporting this event.
youtu.be/MppfJGqAgyw
From MYC-silencing (@RacuraOncology) to 5 confirmed complete responses in pancreatic cancer (@ampliatx) and the world’s only clinical GGTase-1 inhibitor (@PTX_AUS), investors heard compelling updates from three ASX oncology companies.
#ASX #TwilightInvestorBriefing
Session 1 | Moderator: Dr Rebecca McQualter - CEO, Chimeric Therapeutics
Presenting: EMVision, @ArgenicaT, iiShield
#BiotechShowcase
Session 2: Investor Panel | Moderator: Michael Woods - CEO, Newburyport Partners
Panelists: Matt McNamara (Horizon 3 Healthcare), Bob Soh (Brandon Capital), Dr Amir Zalcenstein (SYNthesis BioVentures)
#BiotechShowcase
Session 3 | Moderator: Madeleine Williams - Healthcare Analyst, Canaccord
Presenting: @BiotronLimited, @AvechoLtd, @ampliatx, Neuren Pharmaceuticals
#BiotechShowcase
📣 Investor Panel Update: Dr Amir Zalcenstein joins #BiotechShowcase 2026 (3 Sept.) for a timely discussion on the opportunities shaping Australia’s biotech sector.
Waitlist is now open ⬇️
bit.ly/reg-bs26
